Novel Multiplexed LC-MS Assays to Advance Clinical Trials Workflows

Webinar Details
Date: Wednesday, May 22 | 9 AM EST
Location: Virtual

Grace Loxley, Business Development Manager
Ernestas Sirka, Chief Scientific Officer

Registration: Exclusive for Novartis employees only

*Includes live Q&A session

You will learn about the following

Our mission is to generate novel molecular insights that transform drug development and healthcare globally.

We deliver highly accurate, fully quantitative, and definitive targeted biomarker analysis to accelerate the development of life-changing treatments.

Generating Insights that Matter through LC-MS-based Proteomics

  • LC-MS workflows provide clinical grade measurement and absolute quantification down to pg/mL of proteins that are required for regulatory submission

  • Ability to identify multiple epitopes (peptides) per protein to achieve high confidence/high coverage data and insights into lipids, metabolites, and more to support multi-omic analysis


Validated, Versatile, & Adaptable Analysis with LC-MS Assays

  • Can be adapted to provide definitive data into post-translational modifications, other proteins, lipids, and metabolites

  • Suitable for almost any sample type, including blood plasma/serum, cerebrospinal fluid, urine, FFPE, or fresh frozen tissue.


Analytical Validation to Accelerate Clinical Trial Workflows

  • Following the FDA Bioanalytical Method Validation guidelines for data submission

  • CLIA, FDA inspected (US) and GCP/GLP (UK) certified labs

  • Our proprietary analytical algorithms, workflows, and internal standards provide the highest possible reproducibility and robustness across thousands of samples with a linear dynamic range over six orders of magnitude. 

Register Now

Join us and learn how we can help accelerate Novartis’ Therapeutic Development Pipeline.